RIZZARI CARMELO

Ruolo:
Professore straordinario a tempo determinato
Settore scientifico disciplinare:
Pediatria generale e specialistica (MED/38)

Pubblicazioni

  • Rizzari, C., Möricke, A., Valsecchi, M., Conter, V., Zimmermann, M., Silvestri, D., et al. (2023). Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children with Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol. HEMASPHERE, 7(6), 893-895 [10.1097/HS9.0000000000000893]. Dettaglio

  • Locatelli, F., Zugmaier, G., Rizzari, C., Morris, J., Gruhn, B., Klingebiel, T., et al. (2023). Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL. LEUKEMIA, 37(1), 222-225 [10.1038/s41375-022-01770-3]. Dettaglio

  • Moricke, A., Rizzari, C., Alten, J., Attarbaschi, A., Beier, R., Biondi, A., et al. (2023). Hypersensitivity Reactions to Native E. coli L-asparaginase in Children with Acute Lymphoblastic Leukemia Treated in Trial ALL-BFM 2000: Impact of Treatment Schedule and Type of Glucocorticoid in Induction. HEMASPHERE, 7(6), 888-890 [10.1097/HS9.0000000000000888]. Dettaglio

  • Khalil, A., Wurthwein, G., Golitsch, J., Hempel, G., Fobker, M., Gerss, J., et al. (2022). Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia. HAEMATOLOGICA, 107(1 (January, 2022)), 49-57 [10.3324/haematol.2020.258525]. Dettaglio

  • Veltri, G., Sandei, M., Silvestri, D., Bresolin, S., Pession, A., Santoro, N., et al. (2022). NUP214–ABL1 fusion in childhood T-ALL. PEDIATRIC BLOOD & CANCER, 69(9 (September 2022)) [10.1002/pbc.29643]. Dettaglio